NYSE:XTNT
Xtant Medical Holdings, Inc.
XTNT develops and commercializes advanced orthopedic implants and surgical tools for spine and trauma applications in the competitive US medical device market.
Key Metrics
Investment Thesis
Bull Case
XTNT offers exposure to the secular growth of the orthopedic device market with a differentiated product portfolio in high-value spine and trauma categories, and the company retains substantial paid-in capital of $302.7M providing a buffer for future R&D investments or debt reduction initiatives.
Bear Case
Investors should exercise caution due to the sharp deterioration in earnings from 2023 to 2024, coupled with a significant retained earnings deficit of -$259.5M that requires consistent profitability to address, and high interest expense of $4.2M that strains cash flow in a rising rate environment.
About Xtant Medical Holdings, Inc.
Xtant Medical Holdings designs, manufactures, and markets innovative orthopedic solutions including spinal implants, trauma devices, and surgical instruments primarily serving the United States and international markets. The company focuses on high-technology medical devices aimed at improving patient outcomes through minimally invasive surgical techniques.
Analysis
Management Discussion
While the company successfully grew revenue to $117.3M in 2024, representing a strong recovery from 2022 levels, profitability collapsed with a net loss of $16.4M compared to a small profit in 2023. Cash flow from operations turned negative at -$11.9M, suggesting that revenue expansion was not yet generating sufficient cash liquidity to cover capital expenditures and working capital changes.
Industry Overview
The global medical device industry is characterized by rapid technological innovation and consolidation, yet it remains highly regulated with stringent FDA requirements and complex reimbursement structures that impact pricing power and market access for new entrants.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $58.0M | $91.3M | $117.3M |
| Cost of Revenue | $25.8M | $35.8M | $49.1M |
| Gross Profit | $32.1M | $55.5M | $68.2M |
| Operating Expenses | $38.9M | $65.6M | $80.3M |
| Operating Income | $-6.8M | $-10.2M | $-12.1M |
| R&D | $915.0K | $1.3M | $2.4M |
| G&A | $15.5M | $25.9M | $28.7M |
| Marketing | $22.5M | $38.4M | $49.2M |
| Stock-Based Comp | $2.5M | $2.7M | $4.1M |
| D&A | $1.3M | $3.2M | $4.2M |
| Depreciation | $1.2M | $1.8M | $2.5M |
| Amortization | $100.0K | $1.4M | $1.7M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $-1.7M | $9.1M | $-4.2M |
| Interest Expense | $1.7M | $2.9M | $4.2M |
| Interest Income | $31.0K | $149.0K | — |
| Pre-Tax Income | $-8.4M | $-1.0M | $-16.3M |
| Income Tax | $69.0K | $-1.7M | $187.0K |
| Continuing Ops | $-8.5M | $660.0K | $-16.4M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-8.5M | $660.0K | $-16.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-8.5M | $660.0K | $-16.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $49.3M | $64.9M | $67.1M |
| Cash & Equivalents | $20.3M | $5.7M | $6.2M |
| Accounts Receivable | $10.9M | $20.7M | $20.7M |
| Inventory | $17.3M | $36.9M | $38.6M |
| Prepaid Expenses | $673.0K | $1.3M | $1.6M |
| Other Current Assets | $209.0K | $208.0K | $22.0K |
| Long-Term Assets | $10.9M | $27.7M | $26.7M |
| PP&E (Net) | $5.8M | $8.7M | $10.1M |
| Intangibles | $344.0K | $10.1M | $8.4M |
| Goodwill | $3.2M | $7.3M | $7.3M |
| Operating Leases | $1.4M | $1.5M | $829.0K |
| Other LT Assets | $197.0K | $141.0K | $103.0K |
| Total Assets | $60.2M | $92.6M | $93.8M |
| Current Liabilities | $15.2M | $23.0M | $28.6M |
| Accounts Payable | $3.5M | $7.1M | $7.9M |
| Current Debt | $2.3M | — | — |
| Current Leases | $458.0K | $830.0K | $703.0K |
| Other Current Liab | $3.4M | $4.7M | $12.2M |
| Long-Term Liabilities | $10.8M | $18.3M | $22.3M |
| Long-Term Debt | $9.7M | $17.2M | $22.0M |
| LT Operating Leases | $972.0K | $759.0K | $166.0K |
| Other LT Liab | $-3.2M | $-4.3M | $-12.0M |
| Total Liabilities | $26.1M | $41.3M | $50.9M |
| Shareholders' Equity | $34.2M | $51.3M | $43.0M |
| Paid-In Capital | $277.8M | $294.3M | $302.7M |
| Retained Earnings | $-243.7M | $-243.0M | $-259.5M |
| AOCI | — | $29.0K | $-316.0K |
| Total L&E | $60.2M | $92.6M | $93.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-8.5M | $660.0K | $-16.4M |
| Non-Cash Adjustments | $-3.7M | $-27.3M | $3.0M |
| Working Capital Changes | $6.9M | $17.2M | $1.6M |
| Cash from Operations | $-5.3M | $-9.5M | $-11.9M |
| Capital Expenditures | $1.8M | $1.5M | $4.1M |
| Cash from Investing | $-1.6M | $-24.8M | $-3.7M |
| Debt Issuances | — | $4.8M | $5.0M |
| Cash from Financing | $9.0M | $19.7M | $16.1M |
| FX Effect | $0 | $24.0K | $-149.0K |
| Net Change in Cash | $2.1M | $-14.6M | $298.0K |
| Beginning Cash | $18.4M | $20.5M | $5.9M |
| Ending Cash | $20.5M | $5.9M | $6.2M |
Frequently Asked Questions
How does Xtant Medical Holdings, Inc. make money?
Revenue is driven by three core segments: Spine implants which are a primary growth driver, Trauma devices addressing fracture care needs, and Surgical Instruments providing reusable and disposable tools for operating rooms.
What are the main risks for XTNT?
Significant headwinds include the 2024 net loss of $16.4M following a prior profit in 2023, heavy reliance on debt financing evidenced by $22.0M in long-term debt and revolver activity, elevated operating expenses of $80.3M that outpaced revenue growth, and potential regulatory scrutiny or pricing pressure from commercial payers.
What is XTNT's competitive advantage?
The company leverages proprietary technology platforms that reduce surgical complexity and improve recovery times, maintains a robust intellectual property portfolio protecting its innovative designs, and utilizes a direct-to-hospital sales model that eliminates third-party distributor margins.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.